Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2007

View Archived Issues

Synergistic effects of triple antiangiogenic therapy in preclinical models of neovascularization

PRX-302 shows promise for prostate cancer

Intravenous cannabinor shows no efficacy benefit in capsaicin-induced pain

New phase II study for PEP-005 Topical in actinic keratosis

FTC clears Hospira's acquisition of Mayne Pharma

Tentative approval for Barr's generic version of Kytril

Bionovo opens pharmacokinetics study of MF-101

Nalbuphine ER begins phase I safety study for pain

Bayer Schering signs agreement for novel neurodegenerative imaging compounds

MBP-8298 cleared to begin U.S. phase III study in secondary progressive MS

Recent Janssen and Aska patents report new therapeutic agents for urological disorders

Recent Merck, Ambrilia and AnorMED patents disclose novel therapeutics for HIV infection

Safety data from the STAR study presented

No benefit of adding bevacizumab to standard therapy in pancreatic cancer

New treatment options for cardiovascular disorders imparted in recent patents

Addition of bevacizumab to chemotherapy improves progression-free survival in MCRC patients

Final results from the ACTS-GC trial announced

AnGes inlicenses Naglazyme for Japan

Iomai awarded contract for adjuvant patch for use with pandemic influenza vaccine

Novel orally active oxytocin receptor antagonist profiled at GlaxoSmithKline

Novartis and Mochida to copromote Diovan in Japan

Johns Hopkins team reports favorable data on pancreatic cancer vaccine

FDA grants orphan drug status for droxidopa in neurogenic orthostatic hypotension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...